Search clinical trials for: ABBV-3373

Total 434 results

NantPharma, LLC

Terminated

QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma

Clear Cell Sarcoma

United States
National Enzyme Company

Unknown

Study to Investigate the Efficacy of Digestive Enzymes on Inflammation After a Meal

Post Prandial Inflammation Markers

Canada
AbbVie

Completed

A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants

Healthy Volunteers

United States
AbbVie

Completed

A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants

Healthy Volunteers

United States
AbbVie

Active, not recruiting

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

Myelofibrosis (MF)

United States, Argentina, Australia, Brazil, Bulgaria, Chile, Hungary, Israel, Italy, Japan, Spain, Sweden, Turkey, Korea, Republic of
Idorsia Pharmaceuticals Ltd.

Terminated

Tezosentan in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, France, Switzerland
Fundació Sant Joan de Déu

Recruiting

Effects of the Postbiotic Blend ABB C3 on Adiposity and Glucose Metabolism in Children and Adolescents (PostOb)

Obesity, Childhood | Obesity, Adolescent

Spain
AbbVie

Recruiting

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (LIVIGNO-4)

Non-Small Cell Lung Cancer

United States, Israel, Japan, Taiwan
Cairo University

Unknown

Ridge Preservation In Mandibular Molars Using Mixture Of ABB And Autogenous Particulate VS Sticky Bone

Alveolar Bone Loss | Alveolar Bone Resorption | Bone Graft Failure
AbbVie (prior sponsor, Abbott)

Completed

A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies

HCV Infection

United States, Puerto Rico
Amgen

Completed

A Study of AMG 337 in Subjects With Advanced Solid Tumors

Cancer | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology Patients

United States
Pfizer

Completed

Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease

Alzheimer Disease

Australia, France, Spain, United States, South Africa, Italy, Argentina, Poland, Finland, United Kingdom, Canada
AbbVie

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Juvenile Psoriatic Arthritis

United States, Spain, Poland, Italy, Germany, Australia
NuCana plc

Completed

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Colorectal Neoplasms | Colorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, Colorectal

United States, France, United Kingdom
Bausch Health Americas, Inc.

Completed

Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC) (OIC)

Constipation

United States
University of Manitoba

Completed

Online Chronic Pain Therapy for Adults

Chronic Pain

Canada
Intra-Cellular Therapies, Inc.
National Institute on Drug Abuse (NIDA)

Recruiting

A PET Study Following a Single Oral Dose of ITI-333 in Healthy Subjects

Healthy Volunteers

United States
Kymera Therapeutics, Inc.

Recruiting

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

Solid Tumors | T-cell Prolymphocytic Leukemia (T-PLL) | Non Hodgkin Lymphoma (NHL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-Cell Lymphoma (CTCL) | Large Granular Lymphocytic Leukemia (LGL-L)

United States
Seoul National University Hospital

Terminated

Phase 1 and Phase 2 Clinical Trials of SNUBH-NM-333(18F)

Alzheimer Disease

Korea, Republic of
Indiana University
National Institute on Aging (NIA); Indiana University Health; Regenstrief Institute...

Recruiting

Aging Brain Care Virtual Program (ABCV)

Dementia | Alzheimer Disease

United States
Brown University
National Institute on Drug Abuse (NIDA); The Miriam Hospital

Recruiting

Open Trial to Improve Retention in Care for Persons With HIV Who Use Substances

Hiv | Substance Use Disorders

United States
University of Alabama at Birmingham
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaborators

Completed

Acceptance-based Care for Child Eating and Physical Activity Treatment (ACCEPT)

Pediatric Obesity | Executive Function | Self-Regulation

United States
University of Florida
Inventiva Pharma

Completed

Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

Nonalcoholic Fatty Liver Disease (NAFLD) | Type 2 Diabetes (T2DM)

United States
Universidad de Granada

Completed

Clinical Study on the Use of Symbios Xenograft for Sinus Floor Elevation

Sinus Floor Augmentation

Spain
AbbVie
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers

Healthy

Japan, Korea, Republic of
AbbVie

Recruiting

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis (UnlIMMited)

Scalp Psoriasis | Genital Psoriasis

United States
AbbVie

Terminated

A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 (AIM-PMR)

Polymyalgia Rheumatica

United States, Australia, Austria, Canada, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Spain, United Kingdom
Intra-Cellular Therapies, Inc.
National Institute on Drug Abuse (NIDA)

Recruiting

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers

Healthy Volunteers

United States
Intra-Cellular Therapies, Inc.
National Institute on Drug Abuse (NIDA)

Completed

Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers

Healthy Volunteers

United States
Celldex Therapeutics

Terminated

A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Advanced Head and Neck Squamous Cell Carcinoma

United States
AbbVie

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

United States, Korea, Republic of, Taiwan, Israel, Switzerland, United Kingdom, Puerto Rico, Turkey, Spain, Bulgaria, Belgium, Germany, France
AbbVie

Completed

A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China

Healthy Volunteers

China
AbbVie

Recruiting

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2)

Hepatocellular Carcinoma

United States, Taiwan, Spain, France, Italy
AbbVie
Drugs for Neglected Diseases initiative

Terminated

Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection

Onchocerciasis

Congo, The Democratic Republic of the
AbbVie
Pfizer

Active, not recruiting

An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

Cancer | Non-small Cell Lung Cancer (NSCLC)

United States, Israel, Japan, Korea, Republic of, Spain, Taiwan
AbbVie

Completed

Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement (IMMprint)

Psoriasis

United States, Canada, Puerto Rico, Spain
AbbVie

Completed

A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults

Healthy Volunteer

United States
AbbVie

Completed

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

Parkinson's Disease (PD)

United States, Australia
AbbVie

Completed

A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (DETERMINED 1)

Hidradenitis Suppurativa

United States, Australia, Canada, France, Germany, Japan, Netherlands, Spain
Mayo Clinic

Completed

Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma

Melasma

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Chronic Hepatitis C Virus Infection

United States, Puerto Rico
University of Roma La Sapienza

Not yet recruiting

A Prospective muLticEnter Registry in chrONic coronARy synDrOme (LEONARDO)

Coronary Artery Disease
Chong Kun Dang Pharmaceutical

Unknown

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers

Cardiovascular Disease

Korea, Republic of
Chong Kun Dang Pharmaceutical

Unknown

Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers

Cardiovascular Disease

Korea, Republic of
AbbVie
Boehringer Ingelheim

Completed

BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)

Ankylosing Spondylitis (AS)
Brown University
National Institute of Mental Health (NIMH)

Recruiting

Improving Mental Health Among the LGBTQ+ Community

Depression | Anxiety

United States
AbbVie

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

Crohn's Disease

United States, Canada, Israel, Taiwan, Japan, Korea, Republic of, United Kingdom, Serbia
AbbVie

Active, not recruiting

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) (SEQUENCE)

Crohn's Disease (CD)

United States, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Slovakia, South... and more
AbbVie

Completed

A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors

Advanced Solid Tumors Cancer

United States, Australia, France, Taiwan
AbbVie

Enrolling by invitation

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 (OptIMMize-2)

Psoriasis

United States, Canada, Germany, Japan, Poland, Spain, United Kingdom

3

Subscribe